Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET) - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00396110

Purpose

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Condition	Phase
Hypercholesterolemia Coronary Heart Disease	Phase IV

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Resource links provided by NLM:

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol Coronary Artery Disease Heart Diseases

Drug Information available for: Rosuvastatin calcium Rosuvastatin

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment:	3889
Study Start Date:	February 2003

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00396110

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:	Ingrid van Geel, MD	AstraZeneca
Study Chair:	Ingeborg Vosjan, MD	AstraZeneca

More Information

No publications provided

Study ID Numbers:	25V06, TARGET
Study First Received:	November 3, 2006
Last Updated:	November 3, 2006
ClinicalTrials.gov Identifier:	NCT00396110 History of Changes
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AstraZeneca:

cholesterol
coronary heart disease
rosuvastatin
LDL-C goal
hypercholesterolemia

Study placed in the following topic categories:

Antimetabolites
Arterial Occlusive Diseases
Heart Diseases
Hyperlipidemias
Metabolic Diseases
Antilipemic Agents
Myocardial Ischemia
Vascular Diseases
Anticholesteremic Agents
Ischemia

Arteriosclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Rosuvastatin
Metabolic Disorder
Hypercholesterolemia
Coronary Artery Disease
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:

Antimetabolites
Arterial Occlusive Diseases
Heart Diseases
Hyperlipidemias
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Myocardial Ischemia
Vascular Diseases
Enzyme Inhibitors
Anticholesteremic Agents

Arteriosclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Coronary Disease
Rosuvastatin
Therapeutic Uses
Cardiovascular Diseases
Hypercholesterolemia
Coronary Artery Disease
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on September 01, 2009